Efficacy, safety, and dose comparison of degarelix for the treatment of prostate cancer: A systematic review and meta-analysis

Table 3 Pooled adverse events for degarelix (240/80 mg) relative to goserelin (3.6 mg), leuprolide (7.5 mg), and degarelix (240/160 mg)

AEs	Degarelix (240/80 mg) vs goserelin (3.6 mg)				Degarelix (240/80 mg) vs leuprolide (7.5 mg)				Degarelix (240/80 mg) vs degarelix (240/160 mg)
	Stusies (n)	Heterogeneity	OR (95%CI)	P-value	Studies (n)	Heterogeneity	OR (95%CI)	P-value	Studies (n)	Heterogeneity	OR (95%CI)	P-value
Treatment-emergent AEs	3	I² = 0%, P = 0.64	0.62 (0.40, 0.95)	0.03	1	Not applicable	1.07 (0.67, 1.71)	0.78	3	I² = 0%, P = 0.97	0.80 (0.53, 1.2)	0.29
Injection site reactions	3	I² = 0%, P = 0.79	33.08 (15.01, 72.93)	< 0.00001	1	Not applicable	108.96 (14.96, 793.44)	< 0.00001	3	I² = 44%, P = 0.17	0.81 (0.60, 1.09)	0.16
Hot flush	3	I² = 0%, P = 0.59	0.80 (0.50, 1.28)	0.35	1	Not applicable	1.26 (0.80, 2.00)	0.32	3	I² = 11%, P = 0.32	1.23 (0.89, 1.70)	0.22
Weight increase	-	-	-	-	1	Not applicable	0.70 (0.37, 1.34)	0.28	3	I² = 17%, P = 0.30	1.13 (0.72, 1.76)	0.6
Hypertension	-	-	-	-	1	Not applicable	1.48 (0.59, 3.71)	0.4	2	I² = 0%, P = 0.88	0.79 (0.44, 1.42)	0.44
Constipation	-	-	-	-	1	Not applicable	0.57 (0.20, 1.60)	0.29	2	I² = 0%, P = 0.45	0.40 (0.19, 0.84)	0.02
UTI	1	Not applicable	0.08 (0.00-1.88)	0.12	1	Not applicable	0.52 (0.23, 1.15)	0.1	2	I² = 0%, P = 0.45	3.05 (0.97, 9.61)	0.06
Incidence of PSA recurrence	-	-	-	-	1	Not applicable	0.56 (0.29, 1.09)	0.09	-	-	-	-
Incidence of death	-	-	-	-	1	Not applicable	0.53 (0.17, 1.60)	0.26	-	-	-	-

AEs: Adverse events; PSA: Prostate-specific antigen; OR: Odds ratios.